The transaction, which is expected to close by the end of the month, will value the five-yearold company at $500-600 million, according to multiple sources aware of the development.
PharmEasy is closing in on $120m in equity round
More from Industry NewsMore posts in Industry News »
- India tops the chart for approved biosimilars and clinical trials surpassing USA and Europe: 10th Annual Pharma IPR India Conference
- India initiates antidumping probe on certain type of steel from Brazil, China, Germany
- BDR Pharma receives DGCI nod for its generic drug BIAPENEM
- AstraZeneca invests in Imperial’s self-amplifying RNA technology with eye on future drugs